Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A user shared their experience with hair loss treatments, including I-PRF injections, mesotherapy, and a topical solution containing Minoxidil and Finasteride. After experiencing side effects, they decided to stop the medicinal treatments and focus on natural alternatives like I-PRF, microneedling, and essential oils.

PP405 is a promising hair loss treatment that may outperform minoxidil and finasteride by reviving dormant follicles and promoting significant regrowth. Results from ongoing trials are awaited, with a potential market release between 2028-2030.

PP405, developed by Pelage Pharmaceuticals, can reactivate dormant hair follicle stem cells and increase hair growth by 20% in eight weeks, unlike minoxidil or finasteride. However, skepticism remains about its effectiveness and availability, with concerns about funding and the timeline for broader access.

Spraying pyrilutamide on the crown area shows noticeable improvement compared to using a dropper. Applying directly to the vertex is challenging without wasting the product.

OP asked if a product from Amazon is sufficient to dilute finasteride. A user advised against using propylene glycol alone, suggesting a pre-made solution instead.

The conversation is about considering pyrilutamide 1% as an alternative treatment for hair loss due to intolerance to 5-alpha reductase inhibitors. Some users suggest it might be effective, while others view it as a temporary solution.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

The user recommends a thickening clay as a great pre-styling product for hair volume and texture, despite its poor hold. They also mention using finasteride and express skepticism about the effectiveness of a shampoo containing saw palmetto and caffeine.

The conversation discusses the potential of kintor pyrilutamide as a promising treatment for hair loss, with ongoing trials in various phases. There is skepticism due to delays in trial results, but the company is actively pursuing further trials.

The user has been using pyrilutamide 0.5% for over 7 weeks, alongside dutasteride, and noticed some hair improvement, particularly at the temples. They plan to continue and possibly try a 1% solution, with no shedding or side effects reported.

A user in their early twenties shared progress after 1 year and 3 months on 1mg daily oral finasteride, reporting no side effects and improvements despite initial shedding. They emphasized the importance of early intervention and noted that results come in waves, with shedding followed by regrowth.

A user shared progress pictures showing significant hair improvement using finasteride and minoxidil, expressing satisfaction with the results. Another user accused them of having a hair transplant.

Pyrilutamide is being discussed as a potential hair loss treatment, but opinions are mixed, with some users skeptical about its effectiveness and the company's credibility. Some users report combining pyrilutamide with other treatments like dutasteride and microneedling, noting improvements, while others remain doubtful.

PP405 is considered a promising hair loss treatment, potentially replacing minoxidil but not finasteride. Users are hopeful for future treatments like GT20029 and VDPHL01, while remaining cautious about effectiveness and side effects.

The conversation discusses using Rogain foam as a solvent for topical finasteride due to an allergy to propylene glycol. The foam's ingredients, including alcohol SD 40B, are considered suitable for dissolving finasteride for easier application without skin irritation.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

Naming a child after hair loss treatments like Propecia and Finasteride, with most users advising against it. The conversation includes humorous and critical responses, suggesting more conventional names.

The user has been using minoxidil and finasteride without success and is now trying a new product called Arata Mitoactive, which contains the ingredient y100. They plan to review its effectiveness themselves due to a lack of existing reviews.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

PP405 is a new hair loss treatment showing early promise with a 20% hair density increase, but skepticism exists due to past failures of similar treatments like Pyrilutamide, RU58841, and Bimatoprost. Users debate its potential effectiveness, with some hopeful due to Google's involvement, while others urge caution without more evidence.

The user has been using finasteride for 30 years and recently added colostrum to their routine, noticing darker hair regrowth. They experienced shedding with minoxidil and advise against its use, while highlighting the benefits and side effects of long-term finasteride use.

IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.

The user is pleased with their hairline design after using oral finasteride, oral and topical minoxidil, vitamin D, and LED therapy. They are also planning a PRP session and considering laser therapy.

Kintor is potentially pursuing a new hair loss treatment, KT-215, while users express skepticism about the speed and reliability of new product releases. There is a general sentiment that Chinese companies might be more promising in delivering timely solutions.

The conversation is a humorous and hopeful prayer for the effectiveness of finasteride in combating hair loss. Participants express gratitude and support for the treatment.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

Pelage Pharmaceuticals is starting Phase 3 trials for PP405 in September 2026, with potential market release by 2030. Users discuss various hair loss treatments like minoxidil, finasteride, RU58841, kx, breezula, and gt20029, expressing hope for future hair restoration.

The user shared progress pictures after 4 months of using 1.25 mg oral Finasteride every other day. Responses indicate hair regrowth and a filling hairline, with one user asking about side effects or shedding.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

Combining therapies like scyllo-inositol, alpha-ketoglutarate, and autophagy-inducing supplements may enhance hair growth and prevent hair loss. Reporting individual results can accelerate progress in hair loss treatments.